KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Payables (2016 - 2025)

Historic Payables for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $37.4 billion.

  • AbbVie's Payables rose 2268.46% to $37.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $37.4 billion, marking a year-over-year increase of 2268.46%. This contributed to the annual value of $31.9 billion for FY2024, which is 422.51% up from last year.
  • As of Q3 2025, AbbVie's Payables stood at $37.4 billion, which was up 2268.46% from $34.2 billion recorded in Q2 2025.
  • Over the past 5 years, AbbVie's Payables peaked at $37.4 billion during Q3 2025, and registered a low of $20.6 billion during Q1 2021.
  • In the last 5 years, AbbVie's Payables had a median value of $27.0 billion in 2023 and averaged $27.3 billion.
  • In the last 5 years, AbbVie's Payables skyrocketed by 6211.56% in 2021 and then skyrocketed by 280.51% in 2024.
  • Over the past 5 years, AbbVie's Payables (Quarter) stood at $22.7 billion in 2021, then grew by 11.84% to $25.4 billion in 2022, then grew by 20.66% to $30.6 billion in 2023, then rose by 4.23% to $31.9 billion in 2024, then grew by 17.1% to $37.4 billion in 2025.
  • Its Payables was $37.4 billion in Q3 2025, compared to $34.2 billion in Q2 2025 and $32.6 billion in Q1 2025.